Cue Biopharma Inc (1UC.MU)
Chart Events
Performance Outlook
| Previous Close | 3.4000 |
| Open | 3.4200 |
| Bid | 3.3000 x N/A |
| Ask | 3.4200 x N/A |
| Day's Range | 3.4200 - 3.4200 |
| 52 Week Range | 2.2800 - 6.2000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 14, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 1UC.MU
Related Research
- GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Fede
- GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that Matteo Levisetti, M.D., senior vice president (SVP) of
- GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Sum
